Biocare Medical, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biocare Medical, LLC - overview
Established
1997
Location
-, CA, US
Primary Industry
Medical Devices & Equipment
About
Biocare Medical, LLC specializes in the development and manufacturing of advanced diagnostic tools, focusing on immunohistochemistry (IHC) applications to enhance the detection of proteins in tissue samples. Biocare Medical, LLC was founded in 1997 and is headquartered in the US. The company develops and manufactures diagnostic products, primarily for immunohistochemistry. In March 2026, Agilent Technologies Inc.
agreed to acquire Biocare Medical, LLC from GHO Capital and Excellere Partners for USD 950 million in cash. Biocare Medical specializes in the development and manufacturing of primary antibodies and detection systems primarily used in immunohistochemistry (IHC) applications. Their core offerings include PromARK™, MACH™ series, and Multiplex IHC™ products, designed for superior sensitivity and specificity in various tissue staining applications. These products cater to healthcare institutions, research laboratories, and diagnostics companies, particularly in cancer diagnostics, where accurate staining is crucial.
Biocare's products are available in North America, Europe, and Asia, addressing diverse needs in the life sciences and pathology sectors. Biocare Medical generates revenue through the sale of its advanced diagnostic products, focusing on IHC detection systems and primary antibodies. The company operates on a B2B basis, selling primarily to healthcare providers, research institutions, and diagnostic laboratories. Clients purchase equipment such as the NeoPATH Pro-Tect HRP Detection Kit or MACH™ detection systems at fixed prices, ensuring predictable revenue streams.
Transactions are executed through direct sales agreements, which may include bulk purchasing options or partnerships with distributors, reflecting the specialized nature of Biocare's products and their importance in the healthcare industry. The 2026 acquisition by Agilent Technologies Inc. will enable Biocare Medical, LLC to expand its operational scale, accelerate innovation in pathology diagnostics, and enhance global reach and customer support.
Current Investors
Excellere Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment
Website
www.biocare.net
Verticals
E-commerce, HealthTech
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Biocare Medical, LLC - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Announced | Biocare Medical, LLC | - | ||||||||
| Add-on, Trade Sale | Completed | Empire Genomics | - | ||||||||
| Secondary Buyout | Completed | Biocare Medical, LLC | - | ||||||||
| Private Debt | Completed | Biocare Medical, LLC | - | ||||||||
| Growth | Completed | Biocare Medical, LLC | - |
Displaying 1 - 5 of 5
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.